Related Experiment Videos
[Life-threatening hyperuricemia during cytostatic leukemia therapy]
Fortschritte Der Medizin
|March 18, 1982
Summary
Prophylactic allopurinol treatment before chemotherapy effectively prevents hyperuricemia in children with lymphoblastic leukemia. Skipping this crucial step led to fatal outcomes in some patients, highlighting its importance.
Area of Science:
- Pediatric Oncology
- Pharmacology
Background:
- Acute lymphoblastic leukemia (ALL) treatment involves cytostatic therapy.
- Tumor lysis syndrome, including hyperuricemia, is a risk during cancer treatment.
Observation:
- Allopurinol prophylaxis was administered 48 hours prior to initial cytostatic therapy in 25 children with ALL.
- In 4 patients, this prophylactic measure was omitted.
- Two additional patients experienced moderate hyperuricemia during or after chemotherapy.
Findings:
- Prophylactic allopurinol consistently prevented hyperuricemia in all 25 children.
- Two of the 4 patients not receiving prophylactic allopurinol died from hyperuricemia complications.
- Long-term allopurinol treatment was required for moderate hyperuricemia in 2 patients.
Implications:
- Prophylactic allopurinol is essential for preventing hyperuricemia during initial ALL chemotherapy.
- Parental administration of allopurinol is strongly recommended for severely ill leukemic patients.
- Allopurinol can effectively manage moderate hyperuricemia that develops later in treatment or post-chemotherapy.